Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. 1989.
One hundred five patients were enrolled in a 12-week, randomized, prospective, double-blind, placebo-controlled trial of recombinant human gamma-interferon (rHu gamma-IFN) for the treatment of rheumatoid arthritis. Fifty-four patients received rHu gamma-IFN and 51 received placebo. Forty-two patients in each group completed the 12-week trial. Some clinical improvement occurred in both groups of patients. Although the improvement with rHu gamma-IFN was greater than that with placebo, the differences were generally not statistically significant.
Cannon
Grant W
GW
Division of Rheumatology, University of Utah, Salt Lake City, UT 84132, USA.
Pincus
Seth H
SH
Emkey
Ronald D
RD
Denes
Alex
A
Cohen
Selwyn A
SA
Wolfe
Frederick
F
Saway
P Anthony
PA
Jaffer
Adrian M
AM
Weaver
Arthur L
AL
Cogen
Lewis
L
Schindler
John D
JD
D018501:Antirheumatic Agents / Q000266:history* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000266:history*; D004311:Double-Blind Method; D049673:History, 20th Century; D006801:Humans; D007371:Interferon-gamma / Q000266:history* / Q000627:therapeutic use; D015337:Multicenter Studies as Topic / Q000266:history; D010919:Placebos; D016032:Randomized Controlled Trials as Topic / Q000266:history; D011994:Recombinant Proteins
D018501:Antirheumatic Agents; D010919:Placebos; D011994:Recombinant Proteins; D007371:Interferon-gamma